


Claims

1. Use of a compound of formula (I)



(I)

in which:


- 5 A represents a phenyl group optionally substituted by one, two or three substituents chosen from a halogen or a C₁₋₆ alkyl or C₁₋₆ alkoxy group; a thienyl, furyl or pyridyl or a cycloalkyl having from 3 to 8 carbon atoms;
- 10 B represents [lacuna] aminobicyclic group which consists of a 5- or 6-membered cyclic amino compound condensed with a 5- or 6-membered cycloalkyl ring which can have one or two unsaturated bonds, with the condition that B is bonded to the carbon atom of the
- 15 carbonyl group on the nitrogen atom; each R represents a hydrogen atom or the R residues are combined together to form a chemical bond; R₁ represents a hydrogen atom, a C₁₋₆ alkyl group or an aralkyl group having from 7 to 10 carbon atoms; when there are geometrical isomers,
- 20 each geometrical isomer, its E isomers and its Z isomers, its cis isomers and its trans isomers; optionally in the form of an enantiomer or diastereoisomer or of a mixture of these various forms,

1003675E-04030E

including of a racemic mixture, and the addition salts with pharmaceutically acceptable acids of one of these forms,

in the manufacture of a medicament intended for the treatment of inflammation.


2. Use according to Claim 1, characterized in that the compound of formula (I) is the compound:



in which:

- 10 B represents [lacuna] aminobicyclic group which consists of a 5- or 6-membered cyclic amino compound condensed with a 5- or 6-membered cycloalkyl ring which can have one or two unsaturated bonds, with the condition that B is bonded to the carbon atom of the
- 15 carbonyl group on the nitrogen atom; each R represents a hydrogen atom or the R residues are combined together to form a chemical bond; R₁ represents a hydrogen atom, a C₁₋₆ alkyl group or an aralkyl group having from 7 to 10 carbon atoms;
- 20 Y represents a hydrogen atom, a halogen or a C₁₋₆ alkyl or C₁₋₆ alkoxy group and n represents 1, 2 or 3.

3. Use according to Claim 1, characterized in that the compound of formula (I) is the compound



(I)

in which Z represents an ethylene group or a vinylene group.

4. Use according to Claim 1, characterized in that the compound is (S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylicarbonyl)propionic acid.

5. Use according to any one of Claims 1 to 4, characterized in that the medicament is intended for the symptomatic treatment of painful conditions of light to moderate intensity and/or feverish states.

6. Use according to any one of Claims 1 to 4, characterized in that the medicament is intended for the treatment [lacuna] diabetic neuropathies, polyarthrititis, arthrosis, lumbago, traumatological pain and inflammation in the ENT field.